Key Highlights: Taisho Pharmaceutical secures exclusive rights to clinically develop, register, and commercialize Kaigene's next-generation FcRn inhibitor, KG006, in Japan. Kaigene will receive a $5 million upfront payment and is eligible for up to a combined total of $22 million and...
Hence then, the article about kaigene enters into exclusive licensing agreement with taisho pharmaceutical for next generation autoimmune asset kg006 in japan was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan )
Also on site :
- In 1924, Caesar Cardini ran out of kitchen supplies in a Fourth of July rush at his Tijuana restaurant; he tossed romaine with what was left, and the salad carries his name
- Viola Davis, 61, Opens Up About ‘Extremely Painful’ Health Condition for the First Time: ‘It Terrified Me’ (Exclusive)
- Rosalía Shuts Down Kenan Thompson’s Idea for a Pop-Classical Album in Hilarious ‘SNL’ Promo: ‘That’s LUX’